SQZ Biotech Completes Oversubscribed $72 Million Series C FinancingSQZ advancing cell therapy pipeline toward clinical trials in multiple indications Company Board of Directors expands with addition of Marc Elia and Zafi Avnur, PhD WATERTOWN, Mass., August 8, 2018-- SQZ Biotechnologies (SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, announced the completion of an oversubscribed $72 million Series C financing. New investors include Everblue, Illumina Ventures, Invus, Orient Life, and Viva Ventures Biotech Group. Existing investors also participated and include Bridger Healthcare Partners, Global Health Science Fund, GV, JDRF T1D Fund, NanoDimension, and Polaris.